We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
News

Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms

Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
News

Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Their work will also lead to the development of a “dictionary” of genes specific to the disease, according to researchers.

Experts have known for more than a decade that thoracic aortic aneurysms — abnormal enlargements of the aorta in the chest area —run in families and are caused by specific genetic mutations. Until recently, comprehensive testing for these mutations has been both expensive and impractical. To streamline testing, the Aortic Institute collaborated with Dr. Allen Bale of Yale’s Department of Genetics to launch a program to test whole genomes of patients with the condition.

Over a period of three years, the researchers applied a technology known as Whole Exome Sequencing (WES) to more than 100 individuals with these aneurysms. “To our knowledge, it’s the first widespread application of this technology to this disease,” said lead author and cardiac surgeon Dr. John A. Elefteriades, director of the institute.

The researchers detected four mutations known to cause thoracic aortic aneurysms. “The key findings are that this technology can be applied to this disease and it identifies a lot of patients with genetic mutations,” said Elefteriades.

Additionally, the testing program uncovered 22 previously unknown gene variants that likely also contribute to the condition.

Using the test results, the clinicians were able to provide treatment tailored to each patient’s genetic profile. “Personalized aortic aneurysm care is now a reality,” Elefteriades noted. The personalized care ranged from more frequent imaging tests to preventive surgery for those most at risk. “Patients who have very dangerous mutations are getting immediate surgery,” he said.

Given that aneurysm disease is a highly inherited condition, affecting each generation, the researchers offered testing to family members of patients, and found mutations in relatives with no clinical signs of disease.

The researchers anticipate identifying more gene variants over time, accumulating a whole dictionary of mutations. “In a few years, we’re going to have discovered many new genes and be able to offer personalized care to an even greater percentage of aneurysm patients, ” Elefteriades said.

Advertisement